Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Rhythm Pharmaceuticals, the developer of setmelanotide, has successfully pursued regulatory approval for the drug (marketed as IMCIVREE) in conditions caused by upstream defects in the MC4R pathway, such as POMC and LEPR deficiencies, where the receptor itself is intact, and the agonist mechanism is highly effective [57]
Bull Exp Biol Med 2012;153:2558
They are both injectable peptides
You can reach out to our team at any time to learn how we can help address emerging workforce challenges
While diabetes and obesity pose many of the same risks to the body, they arent exactly the same, so its hard to know whether that also influenced the results
On The Pen
US$ 28.22
US$ 22.94
US$ 29.82
US$ 22.91
